Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets.
Arrowhead Pharmaceuticals, Inc.
177 East Colorado Boulevard, Suite 700, Pasadena, CA 91105
CategoryBiotech & Pharmaceuticals
Arrowhead Pharmaceuticals’ environmental impact radiates through its commitment to sustainable research practices and resource efficiency. Through mindful laboratory procedures, energy-conserving operations, and eco-friendly supply chain practices, the company underscores its dedication to minimizing its ecological footprint. Arrowhead Pharmaceuticals’ initiatives to embrace green technologies, optimize resource allocation, and reduce environmental impact underscore its commitment to fostering a greener and more sustainable biopharmaceutical landscape.Arrowhead Pharmaceuticals’ social impact revolves around its mission to transform patient lives and contribute positively to healthcare. By developing groundbreaking biopharmaceutical solutions, the company plays a pivotal role in addressing unmet medical needs and advancing patient care. Furthermore, Arrowhead Pharmaceuticals’ commitment to patient education, diversity and inclusion, and community engagement underscores its dedication to fostering positive societal change and promoting equitable healthcare access.Strong governance and ethical practices form the bedrock of Arrowhead Pharmaceuticals’ operations. The company adheres to rigorous standards of transparency, regulatory compliance, and ethical decision-making. Transparent communication about its products, clinical trials, and ethical considerations speaks to Arrowhead Pharmaceuticals’ commitment to responsible governance, building stakeholder trust, and upholding the highest ethical standards.Arrowhead Pharmaceuticals’ financial sustainability is seamlessly intertwined with its commitment to innovation. The company’s investment in research and development drives advancements in biopharmaceutical solutions, resulting in improved patient care and scientific progress. By embracing strategic financial management and fostering innovation, Arrowhead Pharmaceuticals sustains long-term value creation while propelling the evolution of biopharmaceutical research and development.Arrowhead Pharmaceuticals’ ethical responsibility extends to its biopharmaceutical advancement practices. The company places patient safety, regulatory compliance, and ethical innovation at the forefront of its operations. Through rigorous quality standards in its products and clinical research, Arrowhead Pharmaceuticals ensures ethical practices that prioritize patient well-being and contribute to the overall integrity of the biopharmaceutical industry.